Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    22
    ...
ATC Name B/G Ingredients Dosage Form Price
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 25mg Tablet, film coated 628,918 L.L
N03AX11 TOPAMAX 25 B Topiramate - 25mg 25mg Tablet, film coated 858,715 L.L
V03AC03 DEFEROXAL 180 G Deferasirox - 180mg 180mg Tablet, film coated 13,424,141 L.L
A10BA02 METFORMINE ARROW LAB G Metformin - 500mg 500mg Tablet, film coated 560,382 L.L
C09DA08 VOTUM PLUS B Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 900,374 L.L
N03AX11 TOPIRATE 25 BENTA G Topiramate - 25mg 25mg Tablet, film coated 671,921 L.L
V03AC03 JADENU B Deferasirox - 360mg 360mg Tablet, film coated 63,248,872 L.L
A10BA02 GLUCOPHAGE B Metformin HCl - 850mg 850mg Tablet, film coated 550,821 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 628,918 L.L
N03AX11 TORAMAT G Topiramate - 25mg 25mg Tablet, film coated 522,755 L.L
A10BA02 BROT G Metformin HCl - 850mg 850mg Tablet, film coated 327,898 L.L
C09DA09 EDARBYCLOR B Azilsartan medoxomil - 40mg, Chlortalidone - 12.5mg Tablet, film coated 1,846,440 L.L
N03AX11 TOPAMAX B Topiramate - 50mg 50mg Tablet, film coated 1,914,976 L.L
V03AC03 DEFEROXAL 360 G Deferasirox - 360mg 360mg Tablet, film coated 24,918,561 L.L
C09DA09 EDARBYCLOR B Azilsartan medoxomil - 40mg, Chlortalidone - 25mg Tablet, film coated 1,846,440 L.L
G03AA12 YASMIN B Drospirenone - 3mg, Ethinylestradiol - 30mcg Tablet, film coated 616,824 L.L
N03AX11 TOPIRATE 50 BENTA G Topiramate - 50mg 50mg Tablet, film coated 1,407,835 L.L
A10BA02 DIANORM 850 G Metformin HCl - 850mg 850mg Tablet, film coated 221,286 L.L
C09DB01 EXFORGE B Amlodipine - 5mg, Valsartan - 160mg Tablet, film coated 1,333,092 L.L
N03AX11 TORAMAT G Topiramate - 50mg 50mg Tablet, film coated 1,032,071 L.L
A10BA02 DIANORM 850 G Metformin HCl - 850mg 850mg Tablet, film coated 221,286 L.L
G03AA12 YAZ B Drospirenone - 3mg, Ethinylestradiol - 20mcg Tablet, film coated 1,193,332 L.L
N03AX11 TOPAMAX B Topiramate - 100mg 100mg Tablet, film coated 3,471,145 L.L
P01AB01 FLAGYL B Metronidazole - 500mg 500mg Tablet, film coated 310,428 L.L
A10BA02 DIAPHAGE G Metformin HCl - 850mg 850mg Tablet, film coated 147,823 L.L
J05AB11 VALTREX B Valaciclovir - 500mg 500mg Tablet, film coated 1,169,143 L.L
N03AX11 TOPIRATE 100 BENTA G Topiramate - 100mg 100mg Tablet, film coated 2,559,700 L.L
V03AE02 RENVELA B Sevelamer - 800mg 800mg Tablet, film coated 8,386,876 L.L
C07BB03 TENORETIC B Chlortalidone - 25mg, Atenolol - 100mg Tablet, film coated 291,614 L.L
C09DB01 LOTEVAN G Amlodipine - 5mg, Valsartan - 160mg Tablet, film coated 857,372 L.L
    ...
    22
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025